3- (2,3,5- trichlorophenyl)pyrazine- 2,6- diamine

a potent and selective sodium and calcium channel blocker, in clinical trials as an anticonvulsant and mood stabilizer 8/2007; structure in first source

Also Known As:

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Eller, Mark: 1 article (06/2008)
2.	Foreman, Mark M: 1 article (06/2008)
3.	Hanania, Taleen: 1 article (06/2008)
4.	Stables, James P: 1 article (06/2008)
5.	Stratton, Sharon C: 1 article (06/2008)
6.	White, H Steve: 1 article (06/2008)
7.	Wilcox, Karen S: 1 article (06/2008)

Related Diseases

1.	Drug Resistant Epilepsy 06/01/2008 - "The studies have demonstrated that JZP-4 has greater potency and efficacy than LTG in models of refractory epilepsy, antidepressant activity and antimania activity. " 06/01/2008 - "In the mouse 6-Hz model for drug resistant or refractory epilepsy, JZP-4 had potent anticonvulsant activity at all current intensities, whereas LTG was active at only the lowest current intensity. "
2.	Seizures (Absence Seizure) 06/01/2008 - "In the mouse pentylenetetrazole induced seizures model, JZP-4 was approximately twice as potent as lamotrigine in prolonging the time to clonus. "

Related Drugs and Biologics

1.	Antidepressive Agents (Antidepressants)
2.	Pentylenetetrazole (Metrazol)
3.	Anticonvulsants (Antiepileptic Drugs)
4.	Lamotrigine (Lamictal)